The data revealed that high expression of SH3BP5 was significantly related to age (p = 0.0152), cytogenetics risk (p = 0.0278), and karyotypes (p = 0.0117) of AML patients, and it was a trend toward FAB classifications (p = 0.0801). Here, SH3BP5 is linked to acute myeloid leukemia.